Comparative Pharmacology
Head-to-head clinical analysis: RENFLEXIS versus SIMLANDI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: RENFLEXIS versus SIMLANDI.
RENFLEXIS vs SIMLANDI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Renflexis (infliximab-abda) is a chimeric monoclonal antibody that binds with high affinity to tumor necrosis factor alpha (TNFα), neutralizing its pro-inflammatory activity. It inhibits TNFα binding to its receptors (TNFR1 and TNFR2), reducing inflammatory cell migration, cytokine production, and tissue damage.
SIMLANDI (adalimumab-adbm) is a tumor necrosis factor (TNF) blocker. It binds to TNF-alpha and inhibits its interaction with the p55 and p75 cell surface TNF receptors, thereby reducing inflammatory responses.
5 mg/kg intravenously over at least 2 hours at 0, 2, and 6 weeks, then every 8 weeks.
Subcutaneous injection, 40 mg every 2 weeks; may increase to 40 mg weekly if no response within 4 weeks.
None Documented
None Documented
Terminal elimination half-life approximately 18-21 days (mean ~20 days) in patients with rheumatoid arthritis; supports every-8-week dosing interval.
Terminal elimination half-life is approximately 14 days (range 10–20 days) in patients with rheumatoid arthritis; this supports a subcutaneous dosing interval of every other week.
Primarily eliminated via reticuloendothelial system degradation; renal excretion accounts for <1% of dose as unchanged drug; no significant biliary or fecal excretion.
Adalimumab is eliminated primarily via catabolism to small peptides and amino acids; renal excretion of intact drug is negligible (<1%). Biliary/fecal excretion of intact drug is minimal.
Category C
Category C
TNF-alpha Inhibitor
TNF-alpha Inhibitor